Fig. 2: Physostigmine effects in Bipolar Disorder and Healthy Controls during the inhibition of negative emotions. | Neuropsychopharmacology

Fig. 2: Physostigmine effects in Bipolar Disorder and Healthy Controls during the inhibition of negative emotions.

From: Normalization of impaired emotion inhibition in bipolar disorder mediated by cholinergic neurotransmission in the cingulate cortex

Fig. 2

Panel shows the effects of physostigmine on functional activation and behavioural performance during the inhibition of negative emotions. A increased activation in the right anterior cingulate cortex (BA32, T = 4.62 p < 0.001) in BD receiving physostigmine relative to placebo; and improved behavioral performance in terms of reaction times (p = 0.007); B decreased activation of the right caudate (T = 4.20 p < 0.001) in controls receiving physostigmine relative to placebo. C increased activation within the bilateral dorsal cingulate cortices (BA31, T = 4.11, p < 0.001) and improved accuracy in BD receiving physostigmine relative to placebo (p = 0.027), although still statistically lower than that of controls. BD Bipolar Disorder; HC Healthy Controls. Phys Physostigmine; *pFWE-corr < 0.05; 10 voxel-cluster.

Back to article page